Corcept Therapeutics (CORT) has put relacorilant for Cushing’s syndrome back in front of the FDA, planning to resubmit its New Drug Application after additional analyses and discussions clarified a new six month review timeline.

The recent FDA update and a series of director stock option grants have arrived against a backdrop of strong momentum in the share price, with a 30 day share price return of 46.68% and a 90 day share price return of 91.54%, while the 1 year total shareholder return declined 11.93%. The 3 year total shareholder return is 197.69% and the 5 year total shareholder return is 214.54%.

If this kind of pipeline driven move has your attention, it could be a good moment to see what else is gaining interest through the 35 healthcare AI stocks

With Corcept’s shares up sharply in recent months, an 18% intrinsic discount estimate and a price target above the last close, the key question is whether there is still an opportunity for investors or if markets are already pricing in future growth.

Most Popular Narrative: 8% Overvalued

Compared to the last close of $68.38, the most followed narrative fair value of $63.53 suggests Corcept Therapeutics is pricing in more optimism than that valuation assumes.

Ottima azienda solida finanziariamente senza debiti a lungo e breve termine. Il FcF tende a diminuire nel tempo mentre aumentano i compensi per i vari membri del board che hanno uno skill in the game moderato. Calcolando il DCF , con un approccio un po ottimistico, quindi , valutando la crescita del fcf al 10% per i primi 5 annni e al 7% dal 6 al 10, calcolando un tasso di sconto al 12% e una crescita del 3% annuo (valore in linea con l aumento medio del pil Usa) il mio fair value è di circa 33 euro al quale sottraggo un MoS del 30% , quindi ho impostato l acquisto a 23 euro circa. Anche il P/E di 31 mi da un' indicazione del genere, Quindi attualmente è sopravvalutata.

This narrative, according to Giuca, leans on specific free cash flow paths, a particular discount rate and firm margin assumptions. Curious which inputs really carry the valuation.

Result: Fair Value of $63.53 (OVERVALUED)

However, investors still face key swing factors, including future FDA decisions around relacorilant and any shifts in Corcept’s growth expectations that are already reflected in current valuations.

Another View: Multiples Point To A Rich Price

While the most followed narrative pegs fair value at $63.53, the current $68.38 price also sits above several reference points on sales based metrics. Corcept trades on a P/S of 9.5x versus 5.8x for both peers and the wider US pharmaceuticals group, and above an estimated fair ratio of 13.4x that the market could move towards over time. For you, that gap is really a question about how much valuation risk feels acceptable if growth or sentiment shifts.

To see how those numbers stack up in detail, including how the ratio compares across peers, check out the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With both risks and rewards in play, sentiment on Corcept is clearly split. It makes sense to move quickly and review the data yourself to form a view that fits your own risk tolerance. To help frame that view, take a close look at the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Corcept has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Target potential mispricings across the market by scanning 46 high quality undervalued stocks and see which stocks currently line up with stronger fundamentals.
• Prioritize resilience and capital protection by reviewing the 64 resilient stocks with low risk scores so you can focus on companies with steadier risk profiles.
• Spot under-the-radar opportunities before they hit the spotlight by using the screener containing 22 high quality undiscovered gems to surface ideas others might be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.